Why are migraine patients skipping effective behavioral treatments?

June 05, 2018

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine.

Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred despite the fact that these treatments are considered first-line, safe and effective treatments by medical guidelines.

Those who were referred but did not seek treatment most commonly cited lack of time, cost concerns, and skepticism the treatments will work, according to the new study published in the June 5 issue of Pain Medicine.

An estimated 36 million Americans live with migraines, which are recurrent attacks that cause moderate to severe throbbing pain, and are often accompanied by nausea and/or vomiting and sensitivity to light and sound. Migraines are the sixth most disabling condition worldwide, often resulting in missed work and high utilization of health care services.

Previous research shows that behavioral migraine treatments, including cognitive behavioral therapy (CBT), stress management, relaxation techniques, and biofeedback -- learning to reduce muscle tension with help of a monitoring device -- may reduce symptoms by 50 percent or more. Behavioral treatments can be less costly than medications and have enduring benefits for migraine reduction, according to the researchers, which led them to explore why many patients were not following through on treatment.

"Migraines can be debilitating, so it stands to reason that many patients would want to access a treatment that reduces symptoms by half," says Mia Minen, MD, MPH, an assistant professor of Neurology and Population Health at NYU School of Medicine, and director of research for NYU Langone's Headache Division. "However, our research shows this is far from the case."

Researchers prospectively tracked 234 patients with migraines who presented to an academic headache center, and referred 69 of them for behavioral treatment with a therapist trained in migraines. Fifty-three patients who completed a follow-up interview within three months of their initial appointment were included in the analysis.

Of the patients referred for behavioral treatment, only 30 (56.6 percent) made an appointment. Researchers found no differences between those who started therapy and those who didn't when looking at age, gender, years of suffering from migraines and overall utilization of health care services. However, they did find a significant difference: people who had previously seen a psychologist were more likely to initiate therapy.

Of the patients who did not initiate behavioral treatment, half cited time limitations as a barrier to adherence. In addition to time, patients did not initiate for reasons including cost - since some insurance plans don't cover -- skepticism that it would work, contentment with their current treatment plan, and satisfaction that their headaches were already improving.

Dr. Minen and her colleagues say that more research is needed to develop new methods to overcome these barriers. They add that given concerns about migraine and stigma, research on whether stigma plays a role in limiting patients' abilities to access behavioral treatment should also be explored.

"As providers, we need to develop new ways to present evidence-based behavioral treatments to patients in a similar manner in which pharmacologic therapies are presented, with attention to how behavioral treatments can be part of a larger patient-centered care plan," she said.

Many drugs on the market that reduce or control migraine symptoms often can cause other negative symptoms, according to the authors. A new class of monoclonal antibody medications for migraine, called CGRP inhibitors, have generated excitement among the migraine community as a new treatment option. While these medications have been shown to result in a 50-percent reduction in half of those using them, they are not a cure for migraine; thus, there is a need for creating evidence-based scalable, accessible behavioral treatments, according to the authors.

Other available treatments for migraine include medications, vitamin supplements, and botulinum toxin injections.
This research received no grant funding support; Dr. Minen is a recipient of the American Academy of Neurology-American Brain Foundation Practice Research Training Fellowship, which provides salary support to conduct research.

In addition to Dr. Minen, researchers at NYU School of Medicine included Sarah Azarchi, BS, Rachel Sobolev, BA, Amanda Shallcross, ND, MPH, Audrey Halpern, MD, Thomas Berk, MD, and Naomi M. Simon, MD. Other researchers included Scott Powers, PhD, Richard B. Lipton, MD, and senior author Elizabeth Seng, PhD.

NYU Langone Health / NYU School of Medicine

Related Migraine Articles from Brightsurf:

Disparities in migraine by sexual orientation
Survey data were used to examine the association between sexual orientation (exclusively heterosexual, mostly heterosexual, lesbian, gay or bisexual) and migraine.

Can you paint your migraine?
'Can you draw me a picture of your headache?' may sound like an unusual question - but drawings of headache pain provide plastic surgeons with valuable information on which patients are more or less likely to benefit from surgery to alleviate migraine headaches.

Acupuncture can reduce migraine headaches
Acupuncture can reduce migraine headaches compared to both sham (placebo) acupuncture and usual care, finds a new trial from China published by The BMJ today.

Migraine rats, medical facts
Migraine mechanisms are still far from being fully understood. Escalating data from animal models are 'fact-checking' the neurophysiological and behavioral correlates of the migraine experience in humans, and how they may be affected by current anti-migraine drugs or might translate into new therapies.

Connecting the dots in the migraine brain
This dMRI study pointed to the structural strengthening of connections involving subcortical regions associated with pain processing and weakening in connections involving cortical regions associated with hyperexcitability may coexist in migraine.

Predictors of chronic migraine
A review and meta-analysis found predictors of chronic migraine. Depression, high frequency attacks, medication overuse and allodynia increased the chances for new onset chronic migraine, while annual income -- US$ 50,000 showed a protective effect.

On nitroglycerin, cardiovascular homeostasis and...bam, migraine!
Researchers in Leiden, The Netherlands, found an exaggerated cardiovascular response to nitroglycerin infusion in migraine patients, suggesting an elevated systemic sensitivity to this compound in this population.

All roads lead to migraine
Dr. Samaira Younis, from the Danish Headache Center in Copenhagen, Denmark, shares her research results, which suggests there are no differences between migraine attacks clinical characteristics following administration of 2 different compounds in patients, CGRP and sildenafil, meaning they share common cellular signaling pathways.

Running away from exercise: The curious case of migraine
In spite of the widespread recommendation for regular physical activity as a strategy to manage migraine, for some patients, exercise can instead trigger migraine attacks.

Migraine prevention in children and adolescents
Two medicines already used to prevent migraine in adults also showed efficacy in adolescents with migraine.

Read More: Migraine News and Migraine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.